Clinical Trials

Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Cancer Type

Hematological Malignancy

ClinicalTrials.gov Identifier

NCT06977711

Principal Investigator

Adolfo "Enrique" Diaz Duque, MD, MS

For more information about this study
View Details

About This Study

This study is an investigator-initiated, phase I, single arm, open label clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome, defined as an NCCN-IPI score of 2 or higher.